In the field of cancer, CD9 is suggested as a biomarker for metastatic clear cell renal cell carcinoma, not only to distinguish between cancer subtypes but also to predict the metastatic potential of renal cell carcinoma (80, 81). This evidence concerns the gene CD9 and cancer.